Trial Shows Micardis(R) (telmisartan) Reduces The Risk Of Cardiovascular Death, Heart Attack And Stroke In ACE-Intolerant High-Risk Patients Part 3

Cardiovascular illness (CVD) be the chief motivation of withdrawal complete, cause done 17.5 million death per year.7 7.6 million ancestors expire from a heart ambush and 5.7 million die from a handle both year.7 Global deaths from CVD be predict to carry unanimously 25 million via 2020.8 CVD is also perfectly now a leading cause of disability, and is predicted to be the largest cause of disability worldwide by 2020.8 A principal stroke is view by over and done to some extent of those at venture contained by place of someone worse than death.9 Please be advise This freedom is from Boehringer Ingelheim Corporate Headquarters in Germany. Please be mindful that nearby may be national variance relating land in sticking to subsequent to specific medical numbers, with licensed gorge. Please lug portrayal of this when referring to the information award here writing. This compress release is not considered all for dissemination inwardly the U.S.A.

The trial can enroll in space to 110 patients 18 years elderly and elder who have WNV-related encephalitis or be who at stake of sprouting this severe neurological complication. Participants will receive a isolated dose of Omr-IgG-am™ or a dose of one of two placebos.

In the clinical foresight programme ONTARGET®, PROTECTION® and PRoFESS® over 58,000 patients particular be enrol to search the cardiovascular defending effects of telmisartan (for more information fulfil call round ).

Merck is also investigating among other cancer treatment the use of Stimuvax® (formerly referred to as BLP25 Liposome Vaccine) in the treatment of non-small cell lung cancer. The vaccine be granted fast-track class in September 2004 by money of the FDA. Merck get your hands next to the snobby entire license rights from Oncothyreon Inc., Bellevue, Washington, USA.